Search hospitals

>

Missouri

>

Saint Louis

Washington University

Claim this profile

Saint Louis, Missouri 63110

Global Leader in Cancer

Global Leader in Pancreatic Cancer

Conducts research for Lung Cancer

Conducts research for Solid Tumors

Conducts research for Breast Cancer

1350 reported clinical trials

158 medical researchers

Photo of Washington University in Saint LouisPhoto of Washington University in Saint Louis

Summary

Washington University is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Pancreatic Cancer, Lung Cancer, Solid Tumors, Breast Cancer and other specialties. Washington University is involved with conducting 1,350 clinical trials across 1,564 conditions. There are 158 research doctors associated with this hospital, such as Brian A Van Tine, M.D., Ph.D., Douglas R. Adkins, Premal H Thaker, M.D., M.S., and Ravi Vij, M.D..

Area of expertise

1

Cancer

Global Leader

Washington University has run 95 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
FGFR3 positive
2

Pancreatic Cancer

Global Leader

Washington University has run 71 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
Stage III
FGFR3 positive

Top PIs

Clinical Trials running at Washington University

Breast Cancer

Lung Cancer

Primary Immunodeficiency

Solid Tumors

Colorectal Cancer

Non-Small Cell Lung Cancer

KRAS Mutation

Melanoma

Cancer

Carcinoid Tumor

Image of trial facility.

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria

Image of trial facility.

RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant

for Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

TUB-030

for Cancer

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms

Recruiting

1 award

Phase 1 & 2

3 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Washington University?

Where is Washington University located?

Who should I call to ask about financial aid or insurance network?

What insurance does Washington University accept?

What awards or recognition has Washington University received?